Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions

被引：0
|
作者：
Tu, Hai-Yan
Kai Yin
Ke, E-E
Wu, Si-Pei
Zhao, Xiaotian
Li, Yang-Si
Zheng, Mei-Mei
Liu, Si-Yang Maggie
Sun, Yue-Li
Lin, Jia-Xin
Bai, Xiao-Yan
Zhang, Yi-Chen
Qing Zhou
Yang, Jin-Ji
Zhong, Wenzhao
Wang, Bin-Chao
Zhu, Dongqin
Yang, Lingling
Ou, Qiuxiang
Wu, Yi-Long
机构：
[1] South China Univ Technol, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp,Sch Med, Guangzhou, Peoples R China
[2] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci,Sch Clinical Med 2, Guangzhou, Peoples R China
[3] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[4] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Peoples R China
[5] Nanjing Geneseeq Technol Inc, Geneseeq Res Inst, Nanjing, Peoples R China
[6] Jinan Univ Chinese, Dept Hematol, Sch Med, Affiliated Hosp 1,Inst Hematol,Key Lab Regenerati, Jinan, Peoples R China
[7] Chinese Thorac Oncol Grp CTONG, Guangzhou, Peoples R China
[8] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[9] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[10] Guangdong Prov Peoples Hosp, Dept Guangdong Lung Canc Inst, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2591
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The Co-Occurring Genomic Landscape of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
    Yuan, B.
    Zhao, J.
    Zhou, C.
    Wang, X.
    Zhu, B.
    Zhuo, M.
    Yi, C.
    Zhang, H.
    Dong, X.
    Feng, J.
    Yang, Y.
    Zhou, W.
    Chen, Z.
    Yang, S.
    Zhang, Y.
    Ai, X.
    Chen, K.
    Cui, X.
    Liu, D.
    Wu, W.
    Shi, C.
    Chang, L.
    Li, J.
    Chen, R.
    Yang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S412 - S412
  • [32] Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions.
    Ou, Sai-Hong Ignatius
    Madison, Russell
    Robichaux, Jacqulyne Ponville
    Ross, Jeffrey S.
    Miller, Vincent A.
    Ali, Siraj Mahamed
    Schrock, Alexa Betzig
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
    Kron, A.
    Scheffler, M.
    Ihle, M.
    Michels, S.
    Sueptitz, J.
    Prang, D.
    Jakobs, F.
    Nogova, L.
    Fischer, R. N.
    Eisert, A. K.
    Riedel, R.
    Kron, F.
    Hillmer, A.
    Loges, S.
    Merkelbach-Bruse, S.
    Buettner, R.
    Wolf, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1006 - S1006
  • [34] VEGFA mediates traditional EGFR-TKI resistance in non-small cell lung cancer with EGFR exon 20 insertions
    Yang, Yaning
    Liu, Chengming
    Yang, Guangjian
    Xu, Haiyan
    Lei, Siyu
    Wang, Yan
    CANCER RESEARCH, 2024, 84 (06)
  • [35] Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).
    Zhao, Xin
    Jin, Linling
    Yu, Man
    Ou, Qiuxiang
    Bao, Hua
    Wu, Xue
    Shao, Yang
    Fan, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations
    Yasuhiro Kato
    Gou Yamamoto
    Yasutaka Watanabe
    Yuki Yamane
    Hideaki Mizutani
    Futoshi Kurimoto
    Masahiro Seike
    Akihiko Gemma
    Kiwamu Akagi
    Hiroshi Sakai
    International Journal of Clinical Oncology, 2021, 26 : 1065 - 1072
  • [37] Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations
    Kato, Yasuhiro
    Yamamoto, Gou
    Watanabe, Yasutaka
    Yamane, Yuki
    Mizutani, Hideaki
    Kurimoto, Futoshi
    Seike, Masahiro
    Gemma, Akihiko
    Akagi, Kiwamu
    Sakai, Hiroshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (06) : 1065 - 1072
  • [38] Infrequent ERBB2 mutations in Chinese patients with non-small cell lung cancer
    Feng, Shuidong
    Ling, Hongyan
    Guo, Hui
    Tong, Lingling
    Hu, Guobin
    Liao, Li
    Lv, Xueying
    Tan, Hongzhuan
    Wu, Yimou
    JOURNAL OF THORACIC DISEASE, 2014, 6 (05) : 503 - 506
  • [39] Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions
    Chen, Kaiyan
    Pan, Guoqiang
    Cheng, Guoping
    Zhang, Fanrong
    Xu, Yanjun
    Huang, Zhiyu
    Fan, Yun
    THORACIC CANCER, 2021, 12 (02) : 218 - 226
  • [40] Clinical Outcome of Non-Small Cell Lung Cancer with EGFR/HER2 Exon 20 Insertions Identified in the LC-SCRUM-Japan
    Udagawa, H.
    Matsumoto, S.
    Ohe, Y.
    Satouchi, M.
    Furuya, N.
    Kim, Y. H.
    Seto, T.
    Soejima, K.
    Hayakawa, D.
    Kato, T.
    Miyamoto, S.
    Ohashi, K.
    Saeki, S.
    Ohta, H.
    Fujimoto, D.
    Sekine, A.
    Yoh, K.
    Goto, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S224 - S224
12345